Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $884,473, and 3 were calls, valued at $165,384.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $55.0 for Bristol-Myers Squibb over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $25.0 to $55.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
BMY | PUT | TRADE | NEUTRAL | 01/17/25 | $2.78 | $2.71 | $2.75 | $47.00 | $467.5K | 7.1K | 2.3K |
BMY | PUT | TRADE | NEUTRAL | 08/15/25 | $2.87 | $2.21 | $2.6 | $43.00 | $195.0K | 1.6K | 750 |
BMY | CALL | TRADE | BULLISH | 01/17/25 | $0.93 | $0.87 | $0.91 | $55.00 | $91.0K | 16.3K | 1.0K |
BMY | PUT | SWEEP | BULLISH | 01/17/25 | $2.84 | $2.81 | $2.81 | $47.00 | $73.6K | 7.1K | 512 |
BMY | PUT | SWEEP | BEARISH | 03/21/25 | $4.85 | $4.75 | $4.85 | $50.00 | $61.6K | 181 | 1 |
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
In the last month, 3 experts released ratings on this stock with an average target price of $45.333333333333336.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Bristol-Myers Squibb, Benzinga Pro gives you real-time options trades alerts.
Posted In: BMY